Lipoprotein(a) Genetic Variants Associated With Coronary and Peripheral Vascular Disease But Not Stroke (Heart Protection Study)
Jemma C Hopewell, Robert Clarke · Genetic epidemiology study
BlueRipple Assessment
This genetic study examined whether the LPA gene variants that raise lipoprotein(a) increase risk uniformly across vascular beds — and found a striking anatomical pattern.
Using LPA risk variants in nearly 16,000 people, the investigators found strong, comparable associations with coronary disease and peripheral vascular disease (roughly 19–20 percent higher risk per risk allele), but no association with ischemic stroke. The same genetic driver of Lp(a) affected the coronary and leg arteries but not the cerebral circulation — suggesting Lp(a)‘s atherothrombotic effects are site-specific.
The finding adds nuance to Lp(a)‘s causal story: it is a robust driver of coronary and peripheral atherosclerosis, while its role in stroke is weaker and less consistent. That helps clinicians and trialists target where Lp(a) lowering is most likely to pay off.
We rate the evidence strong. As a genetic (Mendelian-randomization-style) analysis it carries causal weight, refining our understanding of which diseases elevated Lp(a) actually drives.
The original source
Hopewell JC, Clarke R, Parish S, Armitage J, Lathrop M, Hager J, Collins R; Heart Protection Study Collaborative Group. Lipoprotein(a) genetic variants associated with coronary and peripheral vascular disease but not with stroke risk in the Heart Protection Study. Circ Cardiovasc Genet. 2011 Feb;4(1):68-73. doi: 10.1161/CIRCGENETICS.110.958371.
BlueRipple Health provides consumer education and research synthesis for informed health advocacy. This is not medical advice. Discuss all health decisions with a qualified clinician.